Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro
- 1 January 2007
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 17 (1) , 1-10
- https://doi.org/10.1097/01.fpc.0000230110.18957.50
Abstract
The conversion of CPT-11 to its active form, SN-38, by carboxylesterases (CESs) is a critical event in CPT-11-induced cytotoxicity. Among the CESs, CES1 and CES2 probably play a major role in the metabolism, but the functional significance and molecular basis of CES1 on CPT-11 response remain unclear. We investigated CES1A1 (AB119997) and CES1A2 (AB187225), whose coding sequences were recently registered in GenBank, for CPT-11-induced cytotoxicity, anticipating novel biomarkers of CPT-11 response. Their coding sequences showed high homology, with only four amino acid differences in the N-terminal region, but our sequencing study of the 5' regions revealed that CES1A1 and CES1A2 had distinctive consensus sequences for transcription factors in the regions, implying differences in transcriptional regulation of the genes. We also identified three isoforms of CES1A1 gene--CES1A1a, CES1A1b and CES1A1c--and developed a detection method for CES1A1 and CES1A2 types of mRNA expression. Interestingly, CES1A2 type of mRNA was found to be expressed from both CES1A1b and CES1A1c isoforms and CES1A2, the promoter activity of the former was higher than that of the original CES1A2 gene. Finally, CES1A2 type of mRNA expression correlated with CPT-11 sensitivities of cancer cells. We demonstrated novel sequence structures and a functional role of CES1A genes in CPT-11 responses. We believe that our novel findings will be of key importance in developing a really useful prediction method for CPT-11 chemosensitivity.Keywords
This publication has 10 references indexed in Scilit:
- Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer PatientsClinical Cancer Research, 2005
- Pharmacogenomic assessment of carboxylesterases 1 and 2Genomics, 2004
- Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genesInternational Journal of Cancer, 2004
- HYDROLYSIS OF IRINOTECAN AND ITS OXIDATIVE METABOLITES, 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO] CARBONYLOXYCAMPTOTHECIN AND 7-ETHYL-10-[4-(1-PIPERIDINO)-1-AMINO]-CARBONYLOXYCAMPTOTHECIN, BY HUMAN CARBOXYLESTERASES CES1A1, CES2, AND A NEWLY EXPRESSED CARBOXYLESTERASE ISOENZYME, CES3Drug Metabolism and Disposition, 2004
- Enzyme-Catalyzed Activation of Anticancer ProdrugsPharmacological Reviews, 2004
- Cancer pharmacogeneticsBritish Journal of Cancer, 2004
- Structural insights into CPT-11 activation by mammalian carboxylesterasesNature Structural & Molecular Biology, 2002
- Pharmacogenomics: Translating Functional Genomics into Rational TherapeuticsScience, 1999
- THE MAMMALIAN CARBOXYLESTERASES: From Molecules to FunctionsAnnual Review of Pharmacology and Toxicology, 1998
- Telomere shortening in peripheral blood cells was related with aging but not with white blood cell countJournal of Human Genetics, 1996